≥99% HPLCPre-filled pen

AC-Selank-NH2

Name: AC-Selank-NH2
Brand: Dripfy
Availability: InStock

What it is?

AC-Selank-NH2 is a synthetic peptide positioned for anxiolytic and nootropic applications, commonly discussed for its effects on emotional stability and cognition without strong sedative signalling emphasis. It is used in protocols where stress resilience and learning efficiency are primary endpoints.

Dripfy Advantage

BDNF-related modulation: Associated with modulation of brain-derived neurotrophic factor (BDNF) signalling, supporting neuroplasticity frameworks.
Monoamine system influence: Positioned to influence serotonin and dopamine pathway dynamics relevant to mood regulation and cognitive function.
Non-sedating anxiolytic profile: Frequently framed around anxiety reduction signalling without heavy sedation-related endpoints.
Stress-adaptation support: Often positioned for improved stress response modulation and emotional resilience measures in high-pressure contexts.

Clinical Applications & Therapeutic Potential

Anxiety reduction endpoints: Potential support for reduced anxiety markers with maintained functional alertness (protocol-dependent).
Cognitive function outcomes: Potential improvements in clarity, focus, and cognitive efficiency markers.
Stress resilience frameworks: Positioned for improved stress tolerance and emotional regulation endpoints.
Learning and memory formation: Potential support for learning efficiency and memory consolidation markers via neurotrophic signalling pathways.

Composition & Formulation

Peptide Content: 5 mg Selank
Vehicle: Proprietary pH-balanced buffer solution
Delivery System: Pre-filled, multi-dose, closed-system pen
Total Volume: 3 mL
Purity: ≥99% by HPLC/MS

€413

Order by email

Submit an enquiry and we arrange the consultation, physician review and shipping. Physician recommendation required; not medical advice.

Purity: ≥99%
Form: Pre-filled pen
Download Certificate of Analysis: Certificate of Analysis available on request

Important medical notice

A physician recommendation is mandatory before use.
The information on this website is educational only and is not medical advice, diagnosis, or treatment.
Always consult a qualified physician before starting any peptide.
Dosing is individualised and determined by your treating physician.

Peptide Practice Guide

Each card summarises what the peptide is studied for and its evidence strength. It is not a recommendation. Dosing and suitability are decided by your physician.

AC-Selank-NH2

Investigational synthetic anxiolytic and nootropic peptide (tuftsin analogue) · Pre-filled pen

C· Emerging evidence

Selank is a synthetic analogue of the naturally occurring peptide tuftsin, investigated for calming and cognition-supporting signalling without the heavy sedation associated with classical anxiolytics. Laboratory and early clinical work has linked it to modulation of brain-derived neurotrophic factor (BDNF) as well as serotonin and dopamine pathways involved in mood and learning. These are proposed mechanisms drawn from limited research rather than firmly established clinical effects.

Studied use areas

Stress-resilience and adaptation to high-pressure demands
Anxiety-related tension without a primary sedative aim
Attention, learning efficiency and cognitive performance
Emotional stability and balanced mood

Safety & status

Investigational peptide; not approved by EMA or MHRA and studied mainly in regional (Russia/CIS) settings, so long-term safety data are limited.
Nasal or injectable administration should occur only under physician supervision with individual screening.
May interact with mood-, anxiety- or sleep-affecting treatments; disclose all medications to the treating physician.

⚕ Clinical note: This card is educational and is not medical advice, a diagnosis, or a treatment recommendation. AC-Selank-NH2 is investigational; any consideration of it must take place under qualified physician supervision, with dosing and suitability determined individually by the treating physician.

Evidence: Limited human data, mainly from regional (Russia/CIS) clinical use; not EMA/MHRA approved. · References: Peer-reviewed neuropeptide and anxiolytic research literature; Regional (Russia/CIS) clinical studies on Selank; EMA/MHRA regulatory status information